Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07H21/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/139756METHODS AND COMPOSITIONS TO SELECT AND/OR PREDICT COTTON PLANTS RESISTANT TO FUSARIUM RACE-4- RESISTANCE IN COTTON
WO 02.07.2020
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2019/067825 Applicant DOW AGROSCIENCES LLC Inventor ANDERSON, Timothy
This disclosure concerns methods and compositions for identifying cotton plants that have a Fusarium wilt Race 4 resistance trait. Some embodiments concern molecular markers to identify, select, and/or construct Fusarium wilt Race 4 resistant plants and germplasm, or to identify and counter select relatively susceptible plants. This disclosure also concerns cotton plants comprising a Fusarium wilt Race 4 resistance trait that are generated by methods utilizing at least one marker described herein.
2.WO/2020/139897SILENCING TGF-BETA 1 AND COX2 USING SIRNAS DELIVERED IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCER
WO 02.07.2020
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No PCT/US2019/068499 Applicant SIRNAOMICS, INC. Inventor EVANS, David M.
The present invention provides certain pharmaceutical molecules and compositions and methods of using them to treat cancer. The molecules are small interfering RNA (siRNA) molecules that inhibit TGF-beta 1 and Cox2 in humans and other mammals, which are used alone or in combination with immune checkpoint inhibitors, to treat cancer.
3.WO/2020/139783POLYPEPTIDES USEFUL FOR GENE EDITING AND METHODS OF USE
WO 02.07.2020
Int.Class C12N 9/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
Appl.No PCT/US2019/068079 Applicant LIFEEDIT, INC. Inventor BOWEN, Tyson D.
Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.
4.WO/2020/133590METHOD AND TEST KIT FOR QUICKLY PREPARING MONOMOLECULAR OPTICAL SPECTRUM LABELING LIBRARY
WO 02.07.2020
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No PCT/CN2019/071584 Applicant BERRY GENOMICS CO., LTD Inventor MAO, Aiping
Provided is a method for quickly preparing a monomolecular optical spectrum labeling library, comprising the following steps: (1) extracting long genomic DNA; (2) labelling the extracted genomic DNA; (3) purifying the labeled genomic DNA; and (4) staining the backbone of the genomic DNA to obtain a monomolecular optical spectrum labeling library. Also provided is a test kit for preparing the monomolecular optical spectrum labeling library.
5.WO/2020/136170NUCLEOSIDES AND NUCLEOTIDES WITH 3'-HYDROXY BLOCKING GROUPS
WO 02.07.2020
Int.Class C07H 19/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
Appl.No PCT/EP2019/086926 Applicant ILLUMINA CAMBRIDGE LIMITED Inventor FRANCAIS, Antoine
Embodiments of the present disclosure relate to nucleotide and nucleoside molecules with acetal or thiocarbamate 3ʹ-OH blocking groups. Also provided herein are methods to prepare such nucleotide and nucleoside molecules, and the uses of fully functionalized nucleotides containing the 3ʹ-OH blocking group for sequencing applications.
6.WO/2020/139764COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
WO 02.07.2020
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
Appl.No PCT/US2019/067883 Applicant DICERNA PHARMACEUTICALS, INC. Inventor ABRAMS, Marc
This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be either double-stranded or single-stranded and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
7.WO/2020/139871HIGHLY ACCURATE DE NOVO POLYNUCLEOTIDE SYNTHESIS
WO 02.07.2020
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No PCT/US2019/068435 Applicant TWIST BIOSCIENCE CORPORATION Inventor PECK, Bill James
Methods, systems, compositions, and devices for the manufacturing of high-quality building blocks, such as polynucleotides, are described herein. Processes described herein provide for efficient washing of residual reagents, solvents, or byproducts from previous synthetic steps to allow for the generation of polynucleotides with low error rates. Processes described herein also provide for reduction in deletion rates during chemical nucleic acid synthesis. Further, methods and devices described herein allow for the rapid construction and assembly of large libraries of highly accurate polynucleotides.
8.WO/2020/135677OLIGOMERIC NUCLEIC ACID MOLECULE AND APPLICATION THEREOF
WO 02.07.2020
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/CN2019/129025 Applicant RACTIGEN THERAPEUTICS Inventor LI, Longcheng
Provided are a small-activating nucleic acid molecule for treating spinal muscular atrophy, and an application thereof. The small-activating nucleic acid molecule comprises a sense nucleic acid strand and an antisense nucleic acid strand, wherein the sense nucleic acid chain and the antisense nucleic acid chain are respectively oligonucleotide chains having the length of 16-35 nucleotides, and one of nucleotide chains has at least 75% base homology or complementarity with a target selected from a target-gene SMN2 promoter region. Also provided are a pharmaceutical composition comprising the small-activating nucleic acid molecule and an optional medicinal carrier, and a method for up-regulation of an expression of the target gene in a cell and treatment of a disease caused by underexpression of the target gene by using the small-activating nucleic acid molecule or the pharmaceutical composition comprising the small-activating nucleic acid molecule.
9.WO/2020/132487MODIFIED RHODAMINE DYE AND USE THEREOF IN BIOLOGICAL ASSAYS
WO 25.06.2020
Int.Class C09B 11/24
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES; MORDANTS; LAKES
11Diaryl- or triarylmethane dyes
04derived from triarylmethanes
10Amino derivatives of triarylmethanes
24Phthaleins containing amino groups
Appl.No PCT/US2019/067925 Applicant LIFE TECHNOLOGIES CORPORATION Inventor EVANS, Brian
The present invention is directed to f luorescent rhodamine dyes having spectral properties suited to the creation of multiplex assay systems for use in molecular biology, cell biology and molecular genetics. The rhodamine dyes have the following structure:
10.20200199592siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
US 25.06.2020
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 16565318 Applicant Alnylam Pharmaceuticals, Inc. Inventor Yukio Ando

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.